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Abstract
Background: Although orthotopic heart transplantation has been an effective treatment for end-
stage heart failure, the incidence of allograft failure has increased, necessitating treatment options.
Cardiac retransplantation remains the only viable long-term solution for end-stage cardiac allograft
failure. Given the limited number of available donor hearts, the long term results of this treatment
option need to be evaluated.
Methods: 709 heart transplants were performed over a 20 year period at our institution. Repeat
cardiac transplantation was performed in 15 patients (2.1%). A retrospective analysis was
performed to determine the efficacy of cardiac retransplantation. Variables investigated included:
1 yr and 5 yr survival, length of hospitalization, post-operative complications, allograft failure,
recipient and donor demographics, renal function, allograft ischemic time, UNOS listing status,
blood group, allograft rejection, and hemodynamic function.
Results: Etiology of primary graft failure included transplant arteriopathy (n = 10), acute rejection
(n = 3), hyperacute rejection (n = 1), and a post-transplant diagnosis of metastatic melanoma in the
donor (n = 1). Mean age at retransplantation was 45.5 ± 9.7 years. 1 and 5 year survival for
retransplantation were 86.6% and 71.4% respectively, as compared to 90.9% and 79.1% for primary
transplantation. Mean ejection fraction was 67.3 ± 12.2% at a mean follow-up of 32.6 ± 18.5 mos
post-retransplant; follow-up biopsy demonstrated either ISHLT grade 1A or 0 rejection (77.5 ±
95.7 mos post-transplant).
Conclusion: Cardiac retransplantation is an efficacious treatment strategy for cardiac allograft
failure.
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The International Society for Heart Lung Transplantation
(ISHLT) estimates that over 65,000 heart transplants have
been performed worldwide. With the increasing popula-
tion of heart transplant patients there is an associated
large population of patients suffering from allograft fail-
ure resulting from 3 major categories: acute rejection, pri-
mary graft failure, and transplant arteriopathy. Several
clinical and experimental strategies to treat graft failure
have been proposed, but these options have not yet
proven to be long-term clinical solutions. Cardiac retrans-
plantation remains the only viable long-term treatment
for end-stage cardiac allograft failure.
A few studies have evaluated outcomes following cardiac
retransplantation and have demonstrated good results [1-
4]. Unfortunately, the long-term efficacy of heart retrans-
plantation remains unclear with several studies suggesting
significantly worse outcomes [5-8]. Over the past two dec-
ades we have accumulated a significant degree of expertise
in pre-, intra-, and post-operative management of heart
transplant patients at our institution. Our results have
been significantly better than the international mean. We
undertook this retrospective study with the goal of evalu-
ating cardiac retransplantation outcomes at a high volume
center with good results. It is our hope that further evalu-
ation of outcomes will elucidate the viability of ortho-




From April 1987 to May 2007 seven hundred and nine
patients underwent orthotopic heart transplant for end-
stage heart failure from various causes. Etiologies
included ischemic heart disease (42.6%), dilated cardio-
myopathy (55.6%), and other causes (1.8%). During this
same period of time fifteen patients underwent repeat
orthotopic heart transplantation.
Adverse factors, that could potentially limit long-term sur-
vival, were carefully examined and utilized as exclusion
criteria included severe pulmonary hypertension, active or
recent malignancy, evidence of end organ damage due to
diabetes, major chronic disabling illness (e.g. lupus,
severe arthritis, neurologic diseases, previous stroke with
residual deficits), symptomatic peripheral vascular or
carotid artery disease, active mental illness or psychoso-
cial instability, HIV antibodies, intolerance of immuno-
suppression, and history of noncompliance. Only a
fraction of patients felt to be suitable candidates for
retransplantation received organs. Ultimately, whether a
patient was retransplanted was determined primarily by
organ availability and compatibility. Patients who were
not candidates for retransplantation were not supported
by ventricular assist devices.
At the University of Pennsylvania the average waiting time
for heart transplant once listed with UNOS is 7.0 months.
The majority of patients are transplanted within 1 year of
listing (52.0%), while 15.2% of patients are transplanted
within 30 days of listing. Only 5.7% of patients on the
UNOS waiting list expire while awaiting transplantation
at our institution (national average 13.4%).
The majority (50.0%) of patients were UNOS status 1A at
the time of transplantation (14.3% – Status 1B, 35.7% –
Status 2). The average survival of initial grafts, excluding
hyperacute rejection (n = 1) and metastatic melanoma in
the donor (n = 1) as the causes of retransplantation, was
62.1 ± 32.6 months. This study was performed utilizing
existing data available in the University of Pennsylvania
transplantation database along with clinical patient
records.
Operative strategy and patient management
Total ischemic time for allografts prior to reperfusion was
163 ± 29 minutes. 42.9% of all allograft anastomosis were
performed in a bicaval fashion, the remainder were per-
formed with a biatrial anastomosis. Average cardiopul-
monary bypass time was 148 ± 48 minutes.
Myocardial surveillance and pathologic analysis
Myocardial rejection was scored utilizing the ISHLT his-
topathologic grading nomenclature[9]. Myocardial sur-
veillance biopsies were performed once every 2 weeks for
the first 12 weeks, once a month for the remainder of the
1st year, every six months during the 2nd year, and then
annually. Transthoracic echocardiography (TTE) was per-
formed once a month for the 1st 3 months, every 6 months
for the 1st year, and then on an annual basis.
Data analysis
Quantitative data are expressed as mean ± standard error
of the mean (SEM). Variance between two groups was
evaluated using the chi-square test. A p-value of less than
0.05 was considered statistically significant.
Results
Patient demographics
Cardiac retransplantation accounted for 2.1% of all heart
transplants performed at our institution. Primary trans-
plant allograft failure was due to transplant arteriopathy
(66.7%), acute rejection (20.0%), hyperacute rejection
(6.6%), and a post-transplant diagnosis of metastatic
melanoma in the donor[10] (6.6%). 20.3% of recipients
in the primary transplant group were women, as com-
pared to 20% of recipients in the retransplant group.
Mean age at retransplantation was 45.5 ± 9.7 years. Perti-Page 2 of 5
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donor age was 36.7 ± 9.9 years. One-third of all donors in
this study were female.
One patient in this study was supported on extracorporeal
membrane oxygenation (ECMO) for 24 hours, secondary
to hyperacute rejection, while awaiting retransplantation.
There were no untoward sequallae following ECMO.
None of the patients were supported on ventricular assist
devices (VAD).
Post-operative management
Post-operatively patients were recovered in the cardiotho-
racic surgical intensive care unit (CT SICU) until they were
hemodynamically stable for transfer to the cardiothoracic
step-down unit. Mean post-operative cardiac index was
3.4 ± 0.7 l/min/m2. On average patients remained intu-
bated for only 8.6 ± 4.3 hours and remained in the CT
SICU for 3.5 ± 1.0 days. Average length of hospital stay
was 13.2 ± 4.5 days. Patients remained in the hospital in
order to undergo surveillance myocardial biopsies prior to
discharge.
Transthoracic echocardiography was performed 24 hours
following transplantation. Mean ejection fraction imme-
diately following transplant was 65.6 ± 14.2%. Three
patients demonstrated moderately decreased left ventricu-
lar function which resolved prior to hospital discharge
without the assistance of pressors. Two patients had mild
tricuspid regurgitation (TR) while an additional two
patients demonstrated moderate TR. Three out of four
patients with tricuspid regurgitation underwent biatrial
anastomosis, while the remaining patient with moderate
TR had bicaval anastomosis. Mean ejection fraction on
discharge was improved to 68.9 ± 6.8%. All patients
underwent percutaneous endomyocardial biopsies prior
to discharge. Ten patients demonstrated no histopatho-
logic evidence of rejection. Four patients had mild rejec-
tion (ISHLT Grade 1), while 1 patient had moderate
rejection (ISHLT Grade 3A).
There were no major hemodynamic complications fol-
lowing retransplantation necessitating operative reex-
ploration. One patient suffered a mild, non-debilitating
cerebrovascular event without residual deficit. Another
patient required a right sided thoracostomy tube for a
hemothorax. Two patients required hemodialysis for a
short period of time immediately following transplanta-
tion, but regained adequate renal function prior to dis-
charge. Mean 24 hour chest tube output was 525 ± 202 cc.
On average patients were transfused with 3.3 ± 1.6 units
of packed red-blood cells.
Long term patient survival
Patient survival following primary heart transplant at our
institution is 90.9% 1 year following transplant and
79.1% 5 years following transplant. This is better than the
international average heart transplant survival as pub-
lished by the ISHLT for primary cardiac transplantation
with survivals of roughly 85% at 1 year and 70% at 5
years[11]. Patients in this study undergoing cardiac
retransplantation demonstrated 1- and 5-year survivals of
86.6% (p = NS, compared to primary transplants) and
71.4% (p = NS) respectively. Mean ejection fraction was
67.3 ± 12.2% at a mean follow-up of 32.6 ± 18.5 mos
post-retransplan; follow-up biopsy demonstrated either
ISHLT grade 1A or 0 rejection (77.5 ± 95.7 mos post-trans-
plant).
Only 1 patient expired due to failure of the retransplanted
allograft. One day following retransplantation a patient
expired secondary to overwhelming fungal sepsis result-
ing from presumed colonic necrosis. There was 1 late
death 9 months following retransplant resulting from
micronodular cirrhosis diagnosed 4 months following
transplant. Lastly, a patient expired 27 months following
retransplantation due to metastatic lung cancer.
Discussion
As demonstrated in this study, cardiac retransplantation
can be safely performed in appropriately selected patients
with good outcomes. We have demonstrated long term
viability following cardiac retransplantation that
approaches that of primary cardiac transplantation. With
appropriate patient selection, meticulous intra- and post-
operative care, and careful myocardial surveillance cardiac
retransplantation is a very effective and viable treatment
strategy.
Alternate therapeutic options for cardiac allograft failure
are limited as minimal benefits have been demonstrated
with percutaneous coronary interventions, coronary
artery bypass grafting, valvular repair, plasmapheresis, or
medical management [12-15]. There are several promis-
ing experimental strategies, including myocardial regener-
ation and vasculogenesis that may provide novel and
Table 1: Retransplant recipient variables
Gender (female) 20%
Race (Caucasian) 89.4%
Initial Graft Survival (months) 62.1 ± 32.6




Recipient Body Mass Index (kg/m2) 27.9 ± 3.7
Pre-Operative Creatinine (mg/dl) 2.5 ± 1.5
Chronic Renal Insufficiency (Cr>1.5) 60.0%
Diabetes Mellitus 20.0%
Hypertension 66.7%
Hypercholesterolemia 53.3%Page 3 of 5
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cardiac allografts [16-19]. To date, however, these thera-
pies remain experimental and are beyond the current clin-
ical scope. Therefore, the only viable therapy for end-stage
heart failure following a cardiac transplant remains car-
diac retransplantation. Roughly 2.0% of all heart trans-
plants performed annually are cardiac retransplants[11].
The literature on cardiac retransplantation is ambiguous
with several studies reporting divergent findings. Shu-
haiber and colleagues in a retrospective review evaluating
cardiac retransplants found a higher risk of death after
retransplantation when compared to primary allograft
failure. Risk factors for cardiac retransplantation were
ischemic time, age, and ventilator dependence at the time
of transplant, these were similar risk factors for cardiac
transplantation[6]. Optimizing these risk factors with
appropriate patient selection can significantly improve
retransplantation outcomes. Similarly, a smaller study by
Schnetzler and colleagues demonstrated 1- and 4-year sur-
vivals of 61.5% and 46% respectively. Interestingly, the
initial transplant patients in this study had 1 year survival
rates close to 70%, a finding that is significantly lower
than the 85% international average reported by the ISHLT
registry[11]; thereby putting in to question the overall
comparability of the data.
A high volume transplant center published a retrospective
review of their retransplant experience and reported
slightly lower but beneficial short- and long-term results
following cardiac retransplantation[8]. This finding was
corroborated by both a multi-institutional study and sin-
gle center experience that found cardiac retransplantation
to be a viable option for allograft failure secondary to vas-
culopathy[1,3]. Our findings in this study, from a high
volume center with extensive heart transplant experience
and very good long-term results, further support cardiac
retransplantation for allograft failure following a heart
transplant. Admittedly this study is limited by the small
number of patients and retrospective analysis of the data.
Even with this limitation, we have extracted valuable out-
comes that support relisting appropriate patients for car-
diac retransplantation. A large prospective study is
warranted and should be performed, but given the small
number of cardiac retransplantations performed interna-
tionally a study of this magnitude would take several years
to complete.
From a theoretical and immunologic standpoint, retrans-
plantation in a patient with long standing immunosup-
pression may actually provide the appropriate milieu for
diminished rejection, decreased coronary vasculopathy,
and longer allograft survival. One of the most controver-
sial post-transplant issues has been the utilization of
induction therapy with cytolytic anti-lymphocyte anti-
bodies such as OKT3 and thymoglobulin. Encouragingly,
induction therapy has been associated with decreased
rates of allograft rejection[20,21]. But, on the other hand,
utilization of anti-lymphocyte antibodies has been associ-
ated with 9 fold higher rates of lymphoproliferative disor-
ders, bacterial and viral infections, meningitis, and
respiratory distress[22,23]. Based, on this information
one could surmise that a pre-existing immunosuppressed
status would potentiate the beneficial decrease in rejec-
tion seen with induction therapy while avoiding the neg-
ative side effects associated with cytolytic antibodies. If
this theory holds true, then retransplantation from a
purely immunological standpoint would confer greater
long term graft viability.
Along similar lines retransplantation in patients with pro-
longed initial graft survival, ie. greater than 15 years, will
likely have longer retransplant graft function as compared
to patients who suffer hyperacute rejection or repeated
bouts of rejection and rapid onset allograft dysfunction.
Rapid rejection implies a profound immunologic
response with less tolerance of allogenic grafts. A large,
multi-institutional retrospective study found worse sur-
vival in patients undergoing cardiac retransplantation for
early graft failure and acute rejection; with survival rates
for patients that underwent retransplantation <6 months
after initial transplant manifesting worse survival[3].
Therefore, retranplantation performed in a semi-elective
setting for transplant arteriopathy will likely confer better
results than emergent retransplantation performed for
acute rejection. Recipient age does not appear to affect
long-term survival[3].
Cardiac retransplantation raises further interesting man-
agement questions. For instance, does it matter if we do
not resect all of the previous heart? The renal transplant
literature suggests that the presence of multiple organs
from different donors increases the risk of organ rejection.
One can theorize that this situation would hold true for
cardiac retransplants with residual tissue from the initial
donor as well as a heart from a second donor. Therefore,
if a patient has had a biatrial anastomosis at the initial
transplant, should all of the initial donor aorta, pulmo-
nary artery, and atria be resected to decrease immuno-
genicity and rejection associated with the "chimera"? The
literature in both clinical and experimental cardiac trans-
plant models thus far fails to answer these issues. These
questions exemplify our basic understanding of cardiac
retransplantation and the need to expand our knowledge
so that we can optimize outcomes.
Conclusion
In conclusion, cardiac retransplantation is an efficacious
treatment strategy for cardiac allograft failure with good
long-term results.Page 4 of 5
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